MacroGenics Announces Second Interim Overall Survival Data from Phase 3 SOPHIA Study of Margetuximab in Patients with HER2-Positive Metastatic Breast Cancer


You May Also Like

Immuron Progresses Discussions with Institutional Funds

MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian ...

GCC $1.83 Billion In-Vitro Diagnostic Devices Market to 2023

Dublin, Jan. 21, 2019 (GLOBE NEWSWIRE) -- The "GCC In-Vitro Diagnostic Devices Market: Industry ...